7,651.75

-28.75

-0.37%

52,509.00

-323.00

-0.61%

29,397.75

-141.00

-0.48%

Russell 2000 Futures

2,947.50

-16.10

-0.54%

16.49

+0.77

+4.90%

4,446.90

+7.90

+0.18%

78,836.46

+434.57

+0.55%

Crude Oil Oct 26

95.01

+1.98

+2.13%

NasdaqGS - Delayed Quote USD

C4 Therapeutics, Inc. (CCCC)

3.5500 -0.2100 (-5.59%)

At close: September 8 at 4:00:01 PM EDT

3.5700 +0.0200 (+0.56%)

Pre-Market: 7:00:26 AM EDT

Trade CCCC on Coinbase

Loading Chart for CCCC

Chart Range Bar

Interval:

In partnership with ChartIQ

$C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting$

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

Roche and C4 Therapeutics to advance degrader-antibody conjugates research

Roche and C4 Therapeutics to advance degrader-antibody conjugates research

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates

Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential

Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential

C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D

C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

NRIX

PRLD

ARVN

KYMR

GLUE

NKTX

ALXO

CGEM

FATE

FHTX

Mobilize your Website

View Site in Mobile | Classic

Share by: